Merck's tulisokibart showed mid-stage success in hidradenitis suppurativa, with 72% high-dose patients seeing 50%+ abscess ...
Zealand and Roche's petrelintide peaks at 10.7% weight loss at its middle dose in Ph2, trailing Lilly's eloralintide at 20.1% ...
UniQure's shares were rocked Tuesday morning after the company revealed its experimental Huntington’s disease gene therapy ...
At the end of 2027, BioNTech will exit factories in Idar-Oberstein and Marburg and a site in Tübingen that was ...
Beam Therapeutics sued YolTech's Yuxuan Wu & Zi Jun Wang and Serapha Bio for allegedly stealing trade secrets related to ...
Ex-Genentech AI leaders including NYU's Kyunghyun Cho launch health startup Ortet with a $500M commitment from Matt Holt's ...
ARCH and Population Health launch Somnivera with a $10.5M-upfront deal for an ex-China sleep drug from Jiangsu Nhwa.
The cash should give the Stockholm-based biotech a runway “well into 2029,” CEO Patrik Strömberg told Endpoints News in ...
Former House majority leader Eric Cantor has been chosen as PhRMA’s next CEO, according to two sources familiar ...
Breye Therapeutics raised €67.5M Series A; Aptadir raised €40M seed; Ascletis' ASC50 shows psoriasis results; Invivyd touts ...
Bio raises $48M Series A led by UPMC Enterprises & Ziff Capital to target Th17 cells via CD161+ antibody & CAD mRNA platforms ...
Fresenius Kabi will sell biosimilars for Humira, Stelara & Actemra directly to employers via Eversana's Waltz Health, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results